Scarica l'app Stockscreener
8.94
3.71%
0.32
Dopo l'orario di chiusura:
8.92
-0.02
-0.22%
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
Earnings Recap: Is Immix Biopharma Inc benefiting from innovation trendsNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - stockinvest.us
Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation - MSN
IMMX PE Ratio & Valuation, Is IMMX Overvalued - intellectia.ai
Immix Biopharma — Momentum builds with NEXICART-2 progress - Smartkarma
Weekly Earnings: Is Immix Biopharma Inc stock a buy or sell2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Bear Alert: Is Immix Biopharma Inc benefiting from innovation trends2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Citizens reiterates Immix Biopharma stock rating on trial enrollment By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com
Immix Biopharma completes enrollment in AL amyloidosis trial By Investing.com - Investing.com Australia
Immix Biopharma (IMMX) price target increased by 25.64% to 16.66 - MSN
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201 - TipRanks
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy - MSN
Immix completes enrollment in NEXICART-2; topline results expected Q3 2026 - TradingView
[8-K] Immix Biopharma, Inc. Reports Material Event - Stock Titan
Immix Biopharma Completes Enrollment for Key AL Amyloidosis Trial - National Today
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming Milestones - MarketScreener
Immix Biopharma completes enrollment in AL amyloidosis trial - Investing.com
Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA). - Bitget
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - The Manila Times
Mizuho raises Immix Biopharma stock price target on cash position By Investing.com - Investing.com India
Mizuho raises Immix Biopharma stock price target on cash position - Investing.com
Should I trade or invest in Immix Biopharma Inc2026 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Immix Biopharma, Inc. 2025 Annual Report Amendment: Financial Statements, Auditor Correction, and Company Overview - minichart.com.sg
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) widens 2025 loss but ends year with $100M cash - stocktitan.net
Mizuho raises Immix Biopharma stock price target to $15 on cash position - Investing.com Australia
Mizuho raises Immix Biopharma stock price target to $15 on cash position By Investing.com - Investing.com South Africa
Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
H.C. Wainwright raises Immix Biopharma price target to $15 By Investing.com - Investing.com India
Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Immix Biopharma price target to $15 - Investing.com
Citizens reiterates Immix Biopharma stock rating on drug progress By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on drug progress - investing.com
Immix Biopharma (NASDAQ:IMMX) Now Covered by Morgan Stanley - Defense World
Immix Biopharma, Inc. Files Form 8-K Announcing Amendment to ATM Agreement and Legal Opinion – March 25, 2026 - minichart.com.sg
Immix Biopharma, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma’s NXC-201: Next-Generation CAR-T Therapy for AL Amyloidosis and Other Serious Diseases – Pipeline, Strategy, and Clinical Advances - minichart.com.sg
Millennium Management LLC Acquires Significant Stake in Immix Bi - GuruFocus
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):